254 related articles for article (PubMed ID: 35370687)
21. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
22. Second line small molecule therapy options for treating chronic myeloid leukemia.
Molica M; Massaro F; Breccia M
Expert Opin Pharmacother; 2017 Jan; 18(1):57-65. PubMed ID: 27901368
[TBL] [Abstract][Full Text] [Related]
23. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
24. Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance.
Singh VK; Coumar MS
Mini Rev Med Chem; 2019; 19(4):333-345. PubMed ID: 30332954
[TBL] [Abstract][Full Text] [Related]
25. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
26. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2018 Mar; 93(3):442-459. PubMed ID: 29411417
[TBL] [Abstract][Full Text] [Related]
27. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
28. The next generation of therapies for chronic myeloid leukemia.
Quintás-Cardama A; Cortés JE
Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S395-403. PubMed ID: 20007109
[TBL] [Abstract][Full Text] [Related]
29. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
[TBL] [Abstract][Full Text] [Related]
30. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
31. The molecular signature of
Baassiri A; Ghais A; Kurdi A; Rahal E; Nasr R; Shirinian M
iScience; 2024 Apr; 27(4):109538. PubMed ID: 38585663
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.
Amarante-Mendes GP; Rana A; Datoguia TS; Hamerschlak N; Brumatti G
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057108
[TBL] [Abstract][Full Text] [Related]
33. In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study.
Sohraby F; Bagheri M; Aliyar M; Aryapour H
J Mol Graph Model; 2017 Jun; 74():234-240. PubMed ID: 28458002
[TBL] [Abstract][Full Text] [Related]
34. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
35. Targeted drugs in chronic myeloid leukemia.
Gora-Tybor J; Robak T
Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
[TBL] [Abstract][Full Text] [Related]
36. The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.
Teng M; Luskin MR; Cowan-Jacob SW; Ding Q; Fabbro D; Gray NS
J Med Chem; 2022 Jun; 65(11):7581-7594. PubMed ID: 35609336
[TBL] [Abstract][Full Text] [Related]
37. Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
Razga F; Jurcek T; Jeziskova I; Zackova D; Dvorakova D; Borsky M; Mayer J; Racil Z
Mol Diagn Ther; 2012 Jun; 16(3):163-6. PubMed ID: 22489663
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
39. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
[TBL] [Abstract][Full Text] [Related]
40. Validation of a
Outa AA; Abubaker D; Bazarbachi A; Sabban ME; Shirinian M; Nasr R
Haematologica; 2020; 105(2):387-397. PubMed ID: 31101753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
